Is the price fair?
What TSHA's price assumes
Taysha Gene Therapies, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 219× revenue.
219
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 7.73
Price / book · as of 2026-Q1
- EV / sales
- 189
EV / sales
Details›
- Price / book2026-Q1
- 7.73
- EV / EBIToperating margin −1774%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 189
- Market capitalisation
- $1.84B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.